Earlier this month, the results of the first head-to-head biological study, VARSITY, were released at the 2019 European Crohn’s and Colitis Organization (ECCO) Congress. This international event brings together thousands of researchers and stakeholders from around the world to advance research and care.
VARSITY was a population-based trial that studied 767 patients with moderate to severe ulcerative colitis across 37 countries who had not responded to conventional therapy. Researchers found a difference between the treatments across members of this group, where a larger percent of patients treated with vedolizumab (Entyvio®) fared better compared to adalimumab (Humira®).
It is important to remember that everyone experiences Crohn’s and colitis differently. What works for one patient may not work for another—and only the patient themselves and their doctor are able to determine the best treatment plan for the patient’s unique situation.
Ultimately, more research allows these patient-doctor partnerships to make informed decisions, so we encourage those affected by Crohn’s and colitis to continue reading and learning about different treatment options.
To find out more about the results of the VARSITY trial, click here